دورية أكاديمية
أعرض في EDS

The identification and validation of EphA7 hypermethylation, a novel biomarker, in cervical cancer.

التفاصيل البيبلوغرافية
العنوان: The identification and validation of EphA7 hypermethylation, a novel biomarker, in cervical cancer.
المؤلفون: Zhang W; Department of Laboratory Medicine, Tianjin Medical University, Tianjin, China., Cao H; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China., Yang J; Department of Laboratory Medicine, Tianjin Medical University, Tianjin, China., Zhao J; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China., Liang Z; Department of Otorhinolaryngology, Tianjin Medical University General Hospital, Tianjin, China., Kang X; Department of Medical Image, Tianjin Medical University, Tianjin, China., Wang R; Department of Laboratory Medicine, Tianjin Medical University, Tianjin, China. wangrong825@tmu.edu.cn.
المصدر: BMC cancer [BMC Cancer] 2022 Jun 09; Vol. 22 (1), pp. 636. Date of Electronic Publication: 2022 Jun 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: DNA Methylation* , Receptor, EphA7*/genetics , Uterine Cervical Neoplasms*/diagnosis , Uterine Cervical Neoplasms*/genetics, Biomarkers, Tumor ; Cell Line, Tumor ; Female ; Gene Expression Regulation, Neoplastic ; Humans
مستخلص: Background: Aberrant methylation of EphA7 has been reported in the process of carcinogenesis but not in cervical cancer. Therefore, an integration study was performed to explore the association between EphA7 hypermethylation and cervical cancer and validate the potential value of EphA7 hypermethylation in the diagnosis of cervical cancer.
Methods: We performed an integration study to identify and validate the association between EphA7 methylation and cervical cancer. First, data on EphA7 methylation and expression in cervical cancer were extracted and analyzed via bioinformatics tools. Subsequently, CRISPR-based methylation perturbation tools (dCas9-Tet1/DNMT3a) were constructed to further demonstrate the association between DNA methylation and EphA7 expression. Ultimately, the clinical value of EphA7 methylation in cervical cancer was validated in cervical tissues and Thinprep cytologic test (TCT) samples by methylation-specific PCR (MSP) and quantitative methylation-specific PCR (QMSP), respectively.
Results: Pooled analysis showed that EphA7 promoter methylation levels were significantly increased in cervical cancer compared to normal tissues (P < 0.001) and negatively correlated with EphA7 expression. These prediction results were subsequently confirmed in cell lines; moreover, CRISPR-based methylation perturbation tools (dCas9-Tet1/DNMT3a) demonstrated that DNA methylation participates in the regulation of EphA7 expression directly. Consistent with these findings, the methylation level and the positive rate of EphA7 gradually increased with severity from normal to cancer stages in TCT samples (P < 0.01).
Conclusions: EphA7 hypermethylation is present in cervical cancer and is a potential biomarker for the diagnosis of cervical cancer.
(© 2022. The Author(s).)
References: BMC Genomics. 2014 Mar 26;15:119. (PMID: 24669864)
Am J Cancer Res. 2018 Aug 01;8(8):1483-1498. (PMID: 30210918)
Haematologica. 2011 Apr;96(4):558-66. (PMID: 21454882)
Neoplasia. 2017 Aug;19(8):649-658. (PMID: 28732212)
Sci Rep. 2017 Jul 27;7(1):6732. (PMID: 28751638)
Int J Cancer. 2009 Jan 1;124(1):88-94. (PMID: 18821581)
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188417. (PMID: 32828887)
Cancer Res. 2005 Jul 15;65(14):6305-11. (PMID: 16024632)
BMC Cancer. 2008 Mar 25;8:79. (PMID: 18366728)
Cell. 2018 Feb 22;172(5):979-992.e6. (PMID: 29456084)
Oncotarget. 2016 Dec 6;7(49):80735-80750. (PMID: 27738327)
Genome Biol. 2017 May 5;18(1):83. (PMID: 28476144)
Curr Pharm Des. 2018;24(32):3778-3790. (PMID: 30398107)
Clin Epigenetics. 2017 Sep 15;9:99. (PMID: 28932319)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Zhonghua Wai Ke Za Zhi. 2010 Jan 1;48(1):53-6. (PMID: 20302756)
Nat Biotechnol. 2015 May;33(5):510-7. (PMID: 25849900)
Hum Pathol. 2007 Nov;38(11):1649-56. (PMID: 17669470)
Cell. 2016 Sep 22;167(1):233-247.e17. (PMID: 27662091)
Nat Rev Mol Cell Biol. 2019 Oct;20(10):590-607. (PMID: 31399642)
Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92. (PMID: 31701148)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Nat Genet. 2007 Feb;39(2):237-42. (PMID: 17211412)
Epigenetics Chromatin. 2015 Jun 23;8:22. (PMID: 26113876)
Int J Gynaecol Obstet. 2021 Jan;152(1):1-3. (PMID: 33269466)
BMC Clin Pathol. 2014 Feb 04;14(1):8. (PMID: 24495444)
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560. (PMID: 31114875)
Epigenetics. 2015;10(3):229-36. (PMID: 25612142)
Diagn Cytopathol. 2013 Mar;41(3):199-205. (PMID: 21964981)
Mol Med Rep. 2016 Apr;13(4):3190-6. (PMID: 26936314)
Cell. 1999 Oct 29;99(3):247-57. (PMID: 10555141)
BMC Genomics. 2015 Aug 26;16:636. (PMID: 26306699)
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33. (PMID: 15561600)
Cell Death Dis. 2017 Nov 9;8(11):e3167. (PMID: 29120412)
High Throughput. 2018 Oct 26;7(4):. (PMID: 30373182)
Bioinformatics. 2015 Nov 15;31(22):3676-8. (PMID: 26209430)
Oncogene. 2005 Aug 25;24(36):5637-47. (PMID: 16007213)
PLoS One. 2017 Jun 12;12(6):e0175553. (PMID: 28604772)
Gene. 2019 Mar 1;687:193-199. (PMID: 30447346)
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):450-459. (PMID: 33441308)
Sci Rep. 2020 Mar 20;10(1):5181. (PMID: 32198422)
Anticancer Res. 2018 Mar;38(3):1685-1693. (PMID: 29491103)
Cell Death Dis. 2017 Oct 12;8(10):e3122. (PMID: 29022918)
Cancer Res. 2001 Mar 1;61(5):2301-6. (PMID: 11280802)
Nature. 2011 Dec 14;480(7378):490-5. (PMID: 22170606)
J Cell Physiol. 2019 Nov;234(11):20408-20419. (PMID: 31026069)
Methods Mol Biol. 2021;2272:181-194. (PMID: 34009614)
Nucleic Acids Res. 2018 Jan 4;46(D1):D956-D963. (PMID: 29136207)
فهرسة مساهمة: Keywords: CRISPR-dCas9; Cervical cancer; DNA methylation; EphA7
المشرفين على المادة: 0 (Biomarkers, Tumor)
EC 2.7.10.1 (Receptor, EphA7)
تواريخ الأحداث: Date Created: 20220610 Date Completed: 20220613 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9185921
DOI: 10.1186/s12885-022-09653-7
PMID: 35681118
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-022-09653-7